بۆ ناوەڕۆک بازبدە

ئۆکسیندۆلۆن

لە ئینسایکڵۆپیدیای ئازادی ویکیپیدیاوە

ئۆکسیندۆلۆن، بەتەنھا و لەژێر ناوی بازرگانی پرۆستێتین و ڕاکسەنۆن دەفرۆشرێ، دەرمانێکی دژە ئەندرۆجینە و پرۆجستینە کە لە ژاپۆن بۆ چارەسەری گەورە بوونی پرۆستات بەکاردێت[١][٢][٣][٤][٥]ھەرچۆنێک بێت بەکارھێنانەکەی پەسەند نەکراوە بەھۆی کاریگەرییە ھەستیارییەکانی[٦] ئۆکسیندۆلۆن کاریگەر نییە لە ڕێگەی دەمەوە، پێویستە لە ڕێگەی دەرزی لە ماسولکە بدرێت[٧][٨][٩][١٠][١١]

پێکھاتەی دەرمانەکە

ئۆکسیندۆلۆن دژە ئەندرۆجین و دژە وەرگری ئەندرۆجینەکانە، ئامانج دەخاتە سەر ئەندرۆجینەکانی وەکوو تێستۆستیرۆن و دیھایدرۆتێستۆستیرۆن[١٢][١٣][١٤][١٥] ھەروەھا پرۆجستینیشە، ھەروەھا یارمەتی گەشەی پرۆجێستۆجینیش دەدات و چالاکاری وەرگرەکانی پرۆجێسترۆنە، ئامانجەکەی بریتییە لە پرۆجیستۆجینەکان وەکوو پڕۆجێسترۆن[١٦][١٧][١٨][١٩]بەھۆی چالاکییە پرۆجێستۆجینەکانی، ئۆکسیندۆلۆن کاریگەری نەرێنی لەسەر (gonadotropins)ەکان ھەیە[٢٠][٢١]

ئۆکسیندۆلۆن لە ساڵی ١٩٨١ وەکوو دەرمان ناسێنرا[٢٢] و بەتەنھا لە ژاپۆن بەکارھێنرا[٢٣][٢٤]

ئەمانەش ببینە

[دەستکاری]

سەرچاوەکان

[دەستکاری]
  1. ^ J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 914–. ISBN 978-1-4757-2085-3.
  2. ^ William Andrew Publishing (22 October 2013). Pharmaceutical Manufacturing Encyclopedia, 3rd Edition. Elsevier. pp. 2935–. ISBN 978-0-8155-1856-3.
  3. ^ Martin Negwer; Hans-Georg Scharnow (2001). Organic-chemical drugs and their synonyms: (an international survey). Wiley-VCH. p. 2023. ISBN 978-3-527-30247-5.
  4. ^ Tan, MH Eileen; Li, Jun; Xu, H Eric; Melcher, Karsten; Yong, Eu-leong (2014). "Androgen receptor: structure, role in prostate cancer and drug discovery". Acta Pharmacologica Sinica. 36 (1): 3–23. doi:10.1038/aps.2014.18. ISSN 1671-4083. PMC 4571323. PMID 24909511.
  5. ^ Ishizuka, Osamu; Nishizawa, Osamu; Hirao, Yoshihiko; Ohshima, Shinichi (2002). "Evidence-based meta-analysis of pharmacotherapy for benign prostatic hypertrophy". International Journal of Urology. 9 (11): 607–612. doi:10.1046/j.1442-2042.2002.00539.x. ISSN 0919-8172. PMID 12534901.
  6. ^ Ishizuka, Osamu; Nishizawa, Osamu; Hirao, Yoshihiko; Ohshima, Shinichi (2002). "Evidence-based meta-analysis of pharmacotherapy for benign prostatic hypertrophy". International Journal of Urology. 9 (11): 607–612. doi:10.1046/j.1442-2042.2002.00539.x. ISSN 0919-8172. PMID 12534901.
  7. ^ Michael J. Rathbone; Jonathan Hadgraft; Michael S. Roberts (7 November 2002). Modified-Release Drug Delivery Technology. CRC Press. pp. 368–. ISBN 978-0-8247-0869-6.
  8. ^ Henkler G, Klotzbach M, Koch H, Müller W, Richter J (1982). "[Progress in the area of drug development. 15]". Pharmazie (بە ئەڵمانی). 37 (11): 753–65. PMID 6131442. [Oxendolone] has been clinically tested in Japan (weekly intramuscular injection of 200-400 mg) in prostatic hypertrophy.
  9. ^ Hikichi Y, Yamaoka M, Kusaka M, Hara T (2015). "Selective androgen receptor modulator activity of a steroidal antiandrogen TSAA-291 and its cofactor recruitment profile". Eur. J. Pharmacol. 765: 322–31. doi:10.1016/j.ejphar.2015.08.052. PMID 26335395. According to the clinical data of TSAA-291, the plasma level of TSAA-291 after weekly intramuscular administration at 400 mg/kg for 12 weeks is approximately 100 nM (Drug Information).
  10. ^ Ostri P, Swartz R, Meyhoff HH, Petersen JH, Lindgård G, Frimodt-Møller C, Andersson T, Nielsen MS (1989). "Antiandrogenic treatment of benign prostatic hyperplasia: a placebo controlled trial". Urol. Res. 17 (1): 29–33. doi:10.1007/bf00261046. PMID 2466359. Thirty patients were treated with weekly injections of oxendolone 200 mg during a 3 months' period, and 30 patients were allocated to placebo treatment.
  11. ^ Midgley I, Fowkes AG, Darragh A, Lambe R, Chasseaud LF, Taylor T (1983). "The metabolic fate of the anti-androgenic agent, oxendolone, in man". Steroids. 41 (4): 521–36. doi:10.1016/0039-128x(83)90092-2. PMID 6419414. After intramuscular administration of 16β-ethyl-17β-hydroxy-4-[4-14C] estren-3-one (14C-oxendolone; 300 mg) to 3 human subjects, [...]
  12. ^ Annual Reports in Medicinal Chemistry. Academic Press. 8 September 1989. pp. 199–. ISBN 978-0-08-058368-6.
  13. ^ Annual report of Shionogi Research Laboratories. 1991. pp. 76–77.
  14. ^ Kirby, RogerS.; Christmas, Timothy (1991). "The potential value of 5-alpha-reductase inhibition in the treatment of bladder outflow obstruction due to benign prostatic hyperplasia". World Journal of Urology. 9 (1). doi:10.1007/BF00184713. ISSN 0724-4983.
  15. ^ Bashirelahi, N.; Ganesan, S.; Ekiko, D.B.; Young, J.D.; Shida, K.; Yamanaka, H.; Takahashi, E. (1986). "Effect of 16β-ethyl-17β-hydroxy-4-estren-3-one (tsaa-291) on the binding of promegestone (r5020) and methyltrienolone (r1881) to hyperplastic and neoplastic human prostate". Journal of Steroid Biochemistry. 25 (3): 367–374. doi:10.1016/0022-4731(86)90249-9. ISSN 0022-4731.
  16. ^ Annual Reports in Medicinal Chemistry. Academic Press. 8 September 1989. pp. 199–. ISBN 978-0-08-058368-6.
  17. ^ Annual report of Shionogi Research Laboratories. 1991. pp. 76–77.
  18. ^ Kirby, RogerS.; Christmas, Timothy (1991). "The potential value of 5-alpha-reductase inhibition in the treatment of bladder outflow obstruction due to benign prostatic hyperplasia". World Journal of Urology. 9 (1). doi:10.1007/BF00184713. ISSN 0724-4983.
  19. ^ Bashirelahi, N.; Ganesan, S.; Ekiko, D.B.; Young, J.D.; Shida, K.; Yamanaka, H.; Takahashi, E. (1986). "Effect of 16β-ethyl-17β-hydroxy-4-estren-3-one (tsaa-291) on the binding of promegestone (r5020) and methyltrienolone (r1881) to hyperplastic and neoplastic human prostate". Journal of Steroid Biochemistry. 25 (3): 367–374. doi:10.1016/0022-4731(86)90249-9. ISSN 0022-4731.
  20. ^ Sudo, K.; Yamazaki, I.; Masuoka, M.; Nakayama, R. (1979). "IV. EFFECTS OF THE ANTI-ANDROGEN TSAA-291 (16 -ETHYL-17 -HYDROXY-4-OESTREN-3-ONE) ON THE SECRETION OF GONADOTROPHINS". European Journal of Endocrinology. 92 (3 Supplb): S53–S66. doi:10.1530/acta.0.092S053. ISSN 0804-4643. PMID 294107.
  21. ^ Katayama T, Umeda K, Kazama T (November 1986). "[Hormonal environment and antiandrogenic treatment in benign prostatic hypertrophy]". Hinyokika Kiyo (بە ژاپۆنی). 32 (11): 1584–9. PMID 2435122.
  22. ^ William Andrew Publishing (22 October 2013). Pharmaceutical Manufacturing Encyclopedia, 3rd Edition. Elsevier. pp. 2935–. ISBN 978-0-8155-1856-3.
  23. ^ William Andrew Publishing (22 October 2013). Pharmaceutical Manufacturing Encyclopedia, 3rd Edition. Elsevier. pp. 2935–. ISBN 978-0-8155-1856-3.
  24. ^ Ishizuka, Osamu; Nishizawa, Osamu; Hirao, Yoshihiko; Ohshima, Shinichi (2002). "Evidence-based meta-analysis of pharmacotherapy for benign prostatic hypertrophy". International Journal of Urology. 9 (11): 607–612. doi:10.1046/j.1442-2042.2002.00539.x. ISSN 0919-8172. PMID 12534901.